Edwards Lifesciences (EW) reported $1.35 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 8.5%. EPS of $0.67 for the same period compares to $0.59 a year ago. ...

RADNOR, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Edwards Lifesciences Corporation One Edwards Way · Irvine, CA USA · 92614 Phone: 949.250.2500 · www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, CA, Oct. 24, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook • Q3 sales from continuing operations grew 9%; constant currency sales grew 10% 1 • ...

NEWTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences Corporation securities (NYSE: EW) between February 6, 2024, and July 24, 2024, inclusive (the “Class Period”). To join this case, go HERE. Investors who purchased Edwards stock during the Class Period may move the U.S. District Court for the Central District of California to appoint them as the lead ...

SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Edwards Life Sciences Corporation. (NYSE: EW) (“Edwards” or the “Company”) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), charging the Company and certain of its current senior executives with violations of the federal securities laws (collectively, “Defendants”).   Edwards investors have until December 13, 2024 t ...

RADNOR, Pa., Oct. 23, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Edward ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109173&from=3 CLASS PERIO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 23, 2024 (GLOBE ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024. Edwards is an international company that researches, develops, and provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions. For more information, submit a form, ...